Ultragenyx Pharmaceutical's Valuation Gap Widen Amidst Aggressive Growth Forecasts.

Ultragenyx Pharmaceutical (RARE) is expected to post sharp earnings and revenue growth of 81.24% and 28.5% per year, respectively, ahead of the broader US market's 10.5% forecast. Despite being unprofitable, forecasts call for a turnaround with profitability expected within the next three years. The company trades far below its DCF fair value of $361.43, indicating a deep valuation gap based on analyst growth assumptions.